CD274 and cervical carcinoma: SHR-1701, a new bifunctional fusion protein comprised of a monoclonal antibody against PD-L1 linked to the extracellular domain of TGF-β receptor II, was evaluated in a phase I study for patients with advanced cervical cancer who had progressed on one or two lines of platinum-based therapy (or were intolerant to it).